Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

• Status: Recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1b/2, open-label, single arm study to evaluate if enasidenib is safe and effective in improving anemia and decreasing transfusion needs in subjects diagnosed with lower risk myelodysplastic syndrome (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) without a mutation in isocitrate dehydrogenase type 2 (IDH2 wildtype). Other objectives include assessment of improvements in platelet production and characterization of the mechanism of action of enasidenib in enhancing endogenous erythropoiesis.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tian Yi Zhang
• Collaborator: Celgene Corporation

Criteria

Inclusion Criteria:

1. Documented diagnosis of 1) MDS according to WHO/FAB classification that meets IRSS-R classification of very low or lower risk disease; and a diagnosed as de novo or secondary MDS (MDS RS eligible if refractory to or declined luspatercept therapy).

OR 2) Dysplastic (nonproliferative) CMML with WBC <13.0/microL)

2. No disease modifying therapy (HMA, hydrea) within 2 months of starting study

3. Age ≥ 18 years of age

4. ECOG ≤ 3

5. Negative for IDH2 mutation by NGS or multiplex PCR (SNaPshot)

6. Has symptomatic anemia defined as hemoglobin < 10.0 g/dL with any of the following.

oTachypnea oShortness of breath oFatigue oMalaise oWorsening of cardiovascaular function oAsthenia oDyspnea on exertion oAngina oOther subject symptoms the subject reports as being associated with being anemic.

7. Stated willingness to comply with all study procedures and availability for the duration of the study

8. Ability to take oral medication and be willing to adhere to the medication regimen.

9. Females of reproductive potential need to either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with highly effective contraception without interruption, 28 days prior to starting enasidenib, during the study therapy, and for 30 days after last dose of enasidenib.

10. For males of reproductive potential: agreement to use of condoms

11. Adequate organ function defined as:

• Hepatic function: total bilirubin <1.5 x ULN (unless attributable to Gilbert's disease), AST or ALT < 3x ULN

• Renal function: creatinine clearance >30 mL/minute, calculated by Cockcroft-Gault formula

12. Ability to understand and the willingness to sign the IRB approved informed consent document.

13. Women of childbearing potential must have negative urine or serum pregnancy test

Exclusion Criteria:

1. Use of concurrent other erythropoietic agents (including epoetin, darbepoetin), G-CSF within 30 days of study enrollment

2. Less than 3 months of life expectancy

3. Treatment with iron chelation therapy within 56 days of study start

4. Significant cardiac disease (NYHA Class IV congestive heart failure, or unstable angina or myocardial infarction within the last 6 months

5. Harbor IDH2 somatic mutations by NGS or PCR

6. Pregnant or breast feeding

7. Any uncontrolled bacterial, fungal, viral or other infection.

8. No known HIV+ or active hepatitis B or C infection, defined as positive viral load for HBV or HCV or a positive surface antigen (HBsAg) test for hepatitis B.

9. Have other causes of anemia: deficiencies in iron, B12, folate; nutritional deficiencies related to gastric surgery, anorexia nervosa, excessive zinc supplementation; gastrointestinal bleed. If nutritional deficiencies can be corrected, potential participant can be rescreened and enrolled if nutritionally replete and still meets eligibility criteria.

10. Any other medical history, including laboratory results, deemed by the Principal Investigator likely to interfere with their participation in the study, or to interfere with the interpretation of the results